Kadri Altundag
Kadri Altundag
MKA Breast Cancer Clinic, Tepe Prime
Verified email at
Cited by
Cited by
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates
AO Hoff, BB Toth, K Altundag, MM Johnson, CL Warneke, M Hu, A Nooka, ...
Journal of Bone and Mineral Research 23 (6), 826-836, 2008
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
Rituximab-related viral infections in lymphoma patients
S Aksoy, H Harputluoglu, S Kilickap, DS Dede, O Dizdar, K Altundag, ...
Leukemia & lymphoma 48 (7), 1307-1312, 2007
Association between common risk factors and molecular subtypes in breast cancer patients
FP Turkoz, M Solak, I Petekkaya, O Keskin, N Kertmen, F Sarici, Z Arik, ...
The Breast 22 (3), 344-350, 2013
Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis
K Altundag, ML Bondy, NQ Mirza, SW Kau, K Broglio, GN Hortobagyi, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2007
Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy
AO Hoff, BB Toth, K Altundag, V Guarneri, A Adamus, AK Nooka, ...
Journal of Clinical Oncology 24 (18_suppl), 8528-8528, 2006
Aromatase inhibitors in breast cancer: an overview
K Altundag, NK Ibrahim
The Oncologist 11 (6), 553-562, 2006
Manipulating the chemokine‐chemokine receptor network to treat cancer
PA Ruffini, P Morandi, N Cabioglu, K Altundag, M Cristofanilli
Cancer 109 (12), 2392-2404, 2007
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients
IE Smith, JY Pierga, L Biganzoli, H Cortés-Funes, C Thomssen, X Pivot
Ann Oncol 22 (3), 595-602, 2011
Do yoga and aerobic exercise training have impact on functional capacity, fatigue, peripheral muscle strength, and quality of life in breast cancer survivors?
N Vardar Yağlı, G Şener, H Arıkan, M Sağlam, D İnal İnce, S Savcı, ...
Integrative cancer therapies 14 (2), 125-132, 2015
From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures
MC Boruban, K Altundag, GS Kilic, J Blankstein
European Journal of Cancer Prevention 17 (2), 133-138, 2008
Cardiotoxicity of novel HER2-targeted therapies
MAN Sendur, S Aksoy, K Altundag
Current medical research and opinion 29 (8), 1015-1024, 2013
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
B Boyraz, MAN Sendur, S Aksoy, T Babacan, EC Roach, ...
Current medical research and opinion 29 (4), 405-414, 2013
Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with …
E Sari, G Guler, M Hayran, I Gullu, K Altundag, Y Ozisik
Medical Oncology 28, 57-63, 2011
Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension
M Dincer, K Altundag
Annals of Pharmacotherapy 40 (12), 2278-2279, 2006
Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature
C Arslan, E Sari, S Aksoy, K Altundag
Expert opinion on therapeutic targets 15 (1), 21-30, 2011
EGFR expression and gene copy number in triple-negative breast carcinoma
B Gumuskaya, M Alper, S Hucumenoglu, K Altundag, A Uner, G Guler
Cancer genetics and cytogenetics 203 (2), 222-229, 2010
Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor–related arthralgia
O Dizdar, L Özçakar, FÜ Malas, H Harputluoglu, N Bulut, S Aksoy, ...
Journal of Clinical Oncology 27 (30), 4955-4960, 2009
Breast cancer subtypes and outcomes of central nervous system metastases
UY Arslan, B Oksuzoglu, S Aksoy, H Harputluoglu, I Turker, Y Ozisik, ...
The Breast 20 (6), 562-567, 2011
Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients
F Karatas, GU Erdem, S Sahin, A Aytekin, D Yuce, AR Sever, T Babacan, ...
The Breast 32, 237-244, 2017
The system can't perform the operation now. Try again later.
Articles 1–20